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ABSTRACT 
 
 The effect of multiple intramuscular injections of the synthetic  
glucocorticoid, prednisolone (2.2 mg/kg body weight) every alternate 
day, on serum thyroxine (T4), triiodothyronine (T3), thyroid 
stimulating hormone (TSH) and leuteinzing hormone (LH) concentra-
tions in male domestic rabbits were assessed.  
Results revealed that serum T4 and T3 concentrations decreased 
significantly after 6 injections (day 12 of the experiment) of 
prednisolone were made. However, with 3 injections (day 6 of the 
experiment) of prednisolone there were non-significant differences in 
serum T4 and T3 values between the  control and the treated animals. 
Prednisolone treatment also resulted in non-significant reduction in 
the concentration of TSH despite the concomitant profound decrease 
of T4 and T3.  
 Moreover, serum concentration of LH - which is indispensable 
for ovulation and normal gonadal endocrine function - was 
significantly reduced in the treated group compared to the control 
when 3 injections and 6 injections of prednisolone were administered 
to the domestic rabbits. 
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  ﺨـﻼﺼـﺔ ﺍﻷﻁـﺭﻭﺤـﺔ
ﺘﻘﻴﻴﻡ ﺍﺜﺭ ﺍﻟﺤﻘﻥ ﺍﻟﻌﻀﻠﻲ ﺍﻟﻤﺘﻌﺩﺩ ﻟﻠﻬﺭﻤﻭﻥ ﺍﻟﻘﺸﺭﺍﻨﻲ ﺍﻟـﺴﻜﺭﻱ ﺍﻟـﺼﻨﺎﻋﻲ ﺘﻡ   
ﻜﻴﻠﻭﺠﺭﺍﻡ ﻤﻥ ﻭﺯﻥ ﺍﻟﺤﻴﻭﺍﻥ ﺒﻌـﺩ ﻜـل ﻴـﻭﻡ ﻋﻠـﻰ / ﻤﻠﺠﻡ 2.2 )enolosinderP(
ﻭﺍﻟﻬﺭﻤﻭﻥ ﺍﻟﻤﻨﺒـﻪ )3T( ﻭﺍﻟﺜﻴﺭﻭﻨﻴﻥ ﺜﻼﺜﻲ ﺍﻟﻴﻭﺩ )4T( ﺜﻴﺭﻭﻜﺴﻴﻥ  : ﻤﺤﺘﻭﻴﺎﺕ ﺍﻟﻤﺼل
  . ﻓﻲ ﺫﻜﻭﺭ ﺍﻷﺭﺍﻨﺏ ﺍﻷﻟﻴﻔﺔ)HL(  ﻭﺍﻟﻬﺭﻤﻭﻥ ﺍﻟﻤﻠﻭﺘﻥ )HST(ﻟﻠﺩﺭﻗﻴﺔ 
ﻴﻥ ﺜﻼﺜﻲ ﺍﻟﺜﻴﺭﻭﻨ ﺃﻅﻬﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﺃﻥ ﻫﻨﺎﻟﻙ ﻨﻘﺼﺎﻥ ﻤﻠﺤﻭﻅ ﻓﻲ ﺍﻟﺜﻴﺭﻭﻜﺴﻴﻥ ﻭ 
 ﻴﻭﻡ ﻤﻥ ﺒﺩﺍﻴـﺔ 21 )enolosinderPﺍﻟﻴﻭﺩ ﺍﻟﻤﺼﻠﻲ ﺒﻌﺩ ﺍﻟﺤﻘﻥ ﻟﺴﺕ ﻤﺭﺍﺕ ﺒﻭﺍﺴﻁﺔ 
ﺍﻟﺜﻴـﺭﻭﻨﻴﻥ  ﻭﻜﻤﺎ ﻜﺎﻨﺕ ﻫﻨﺎﻟﻙ ﺍﺨﺘﻼﻓﺎﺕ ﻏﻴﺭ ﻫﺎﻤﺔ ﻓﻲ ﻗﻴﻡ ﺍﻟﺜﻴﺭﻭﻜـﺴﻴﻥ ﻭ ( ﺍﻟﺘﺠﺭﺒﺔ
ﺜﻼﺜﻲ ﺍﻟﻴﻭﺩ ﺍﻟﻤﺼﻠﻲ ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺤﻜﻤﺔ ﻤﻥ ﺍﻟﺤﻴﻭﺍﻨﺎﺕ ﻭﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﻌﺎﻟﺠـﺔ 
ﻭﺃﻴﻀﺎﹰ (  ﺃﻴﺎﻡ ﻤﻥ ﺒﺩﺍﻴﺔ ﺍﻟﺘﺠﺭﺒﺔ 6 )enolosinderPﺒﻌﺩ ﺍﻟﺤﻘﻥ ﻟﺜﻼﺙ ﻤﺭﺍﺕ ﺒﻭﺍﺴﻁﺔ 
 ﺍﻨﺨﻔﺎﺽ ﻏﻴﺭ ﻫﺎﻡ ﻓﻲ ﺘﺭﻜﻴـﺯ ﺍﻟﻬﺭﻤـﻭﻥ enolosinderPﻨﺘﺞ ﻋﻥ ﺍﻟﻌﻼﺝ ﺒﻭﺍﺴﻁﺔ 
 ﺍﻟﻤﻨﺒﻪ ﻟﻠﺩﺭﻗﻴﺔ ﻋﻠﻰ ﺍﻟﺭﻏﻡ ﻤﻥ ﺍﻟﻨﻘﺼﺎﻥ ﺍﻟﺸﺩﻴﺩ ﺍﻟﻤﺼﺎﺤﺏ ﻓﻲ ﺘﺭﻜﻴﺯ ﺍﻟﺜﻴﺭﻭﻜـﺴﻴﻥ ﻭ 
  .ﺍﻟﺜﻴﺭﻭﻨﻴﻥ ﺜﻼﺜﻲ ﺍﻟﻴﻭﺩ ﺍﻟﻤﺼﻠﻲ
ﻓﻲ ﺘﺭﻜﻴـﺯ ﺍﻟﻬﺭﻤـﻭﻥ ﻋﻼﻭﺓ ﻋﻠﻰ ﺫﻟﻙ، ﺃﻅﻬﺭﺕ ﺍﻟﻨﺘﺎﺌﺞ ﻨﻘﺼﺎﻥ ﺒﺸﻜل ﻫﺎﻡ   
ﺍﻹﻓﺭﺍﺯﻴـﺔ ( ﺍﻟﻐﺩﺩ ﺍﻟﺘﻨﺎﺴﻠﻴﺔ ) ﺍﻟﺫﻱ ﻻ ﻏﻨﻲ ﻋﻨﻪ ﻟﻼﺒﺎﻀﺔ ﻭﻭﻅﻴﻔﺔ ﺍﻟﻤﻨﺎﺴل -ﺍﻟﻤﻠﻭﺘﻥ 
 ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﻌﺎﻟﺠﺔ ﺒﺎﻟﻤﻘﺎﺭﻨﺔ ﻤﻊ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﻤﺘﺤﻜﻤﺔ ﻋﻨﺩﻤﺎ ﺘﻡ ﺤﻘﻥ –ﺍﻟﻁﺒﻴﻌﻴﺔ 
  . enolosinderPﺍﻷﺭﺍﻨﺏ ﺍﻷﻟﻴﻔﺔ ﻟﺜﻼﺙ  ﻤﺭﺍﺕ ﻭﻟﺴﺕ ﻤﺭﺍﺕ ﺒﺎﻟـ
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INTRODUCTION 
 
 The adrenal cortex synthesizes a variety of steroids from 
cholesterol and releases them into the circulation. The steroids with 
effects on intermediary metabolism are termed "glucocorticoids". The 
major glucocorticoid in most domestic animals is cortisol (Adams, 
2001). 
 Several synthetic glucocorticoids that are more potent than 
cortisol have been developed. Two examples of that are in common 
clinical use are prednisolone and dexamethasone (Laurence et al., 
1999). 
 Glucocorticoids are potent anti-inflammatory and immuno-
suppressive agents. The majority of therapeutic applications for these 
agents fall into these classifications. However, the adverse metabolic 
effects are difficult to separate pharmacologically from the therapeutic 
benefits, making glucocorticoids potent, yet potentially dangerous 
compounds. They are among the most widely used (and misused) 
class of drugs in human and veterinary medicine. Despite this, 
scientific information on glucocorticoid therapy in most domestic 
species is scarce particularly with respect to endocrine side effects 
(Adams, 2001).  
 It should be recognized that local applications also have similar 
systemic effects (Adams, 2001). Unfortunately, in our country so 
many imported and locally blended cosmetic creams containing 
glucocorticoids are used by women. Furthermore, some are taken 
orally for the purpose of depositing fat. Cutaneously applied gluco-
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corticoids causing prompt and profound adrenocortical suppression is 
reported in man and animal (Zenoble and Kemppainen, 1987). 
 An excess of endogenous and exogenous glucocorticoids, 
causes many well-documented biochemical endocrine effects 
(DeNovo and Prasse, 1983; Dandona et al., 1985; Meyer et al., 1990; 
Kemppainen et al., 1991; Kurtdede et al., 2004). Such alterations will 
result in erroneous misleading interpretation of laboratory results.  
Considering these adverse effects of glucocorticoids. Therefore 
this study was  designed to determine the effect; if any, induced by 
prednisolone on thyroid metabolic hormones, thyroid stimulating 
hormone and lutenizing hormone levels in domestic rabbits.    
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CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 The adrenal glands: 
 Each of the adrenal glands weighs about 4 grams, lies at the 
superior poles of the two kidneys and is composed of two distinct 
parts, the adrenal medulla and the adrenal cortex (Guyton and Hall, 
2006). 
 The central 20 percent of the gland, the adrenal medulla is 
functionally related to the sympathetic nervous system; it secretes the 
hormones epinephrine and norepinephrine in response to sympathetic 
stimulation. The adrenal cortex secretes an entirely different group of 
hormones, called corticosteroids. These hormones are all synthesized 
from the steroid cholesterol. Two major types of adrenocortical 
hormones, the mineralocorticoids and the glucocorticoids, are secreted 
by the adrenal cortex. In addition to these, small amounts of sex 
hormones are secreted, especially androgenic hormones (Guyton and 
Hall, 2006).    
 More than 30 steroids have been isolated from the adrenal 
cortex, but two are of exceptional importance to the normal endocrine 
function of the human body: aldosterone, which is the principal 
mineralocorticoid and cortisol, which is the principal glucocorticoid 
(Guyton and Hall, 2006). 
 It was not until the 1920s that the vital importance of the 
adrenal cortex was appreciated and the distinction between the 
hormones of adrenal cortex and medulla was made (Laurence et al., 
1999). 
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1.2 Synthetic pathways of adrenal steroids:  
 Fig. (1) gives the principal steps in the formation of the 
important steroid products of the adrenal cortex: aldosterone, cortisol 
and androgens (Guyton and Hall, 2006). 
 The precursor for all the steroids is cholesterol, which can be 
either taken up from the circulating lipoproteins or synthesized 
endogenously from acetate. Conversion of cholesterol to steroid 
hormones requires a series of enzymatic modifications that occur both 
in the mitochondria and the endoplasmic reticulum. Most of these 
enzymes are members of the cytochrome P450 super family of oxidases 
(Montgomery et al., 1996). 
1.2.1 Pregnenolone: 
 It is the precursor of all steroid hormones in mammals, and 
conversion of cholesterol to pregnenolone is the rate-limiting step in 
steroid hormones synthesis. This is accomplished in mitochondria by a 
multi-enzyme side-chain cleavage (SCC) complex. In humans, 
complete deficiency of SCC activity is fatal without hormone 
replacement therapy, because it causes an inability to synthesize any 
glucocorticoids or mineraocorticoids (Montgomery et al., 1996). 
1.2.2 21-Hydroxylase deficiency: 
 Interestingly, 21-hydroxylase deficiency is associated with a 
tendency to waste salt in urine, whereas, 11 ß-hydroxylase deficiency 
is associated with hypertension. This difference is due to the mineralo-
corticoid effects of 11-deoxycorticosterone (DOC), (Montgomery      
et al., 1996). Patients with the classic form of congenital adrenal 
hyperplasia due to 21-hydroxylase deficiency show excess andreogens 
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Fig (1): Synthetic Pathways of adrenal Steroids 
(From Guyton and Hall , 2006) 
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 (Volkl et al., 2006). This is because, cortisol secretion is reduced and 
feedback leading to the increase of adrenocorticotropic hormone 
(ACTH) secretion to maintain adequate cortisol. This in turn leads to 
diversion of the steroid precursors into the androgenic steroid 
pathways (Kumar and Clark, 2002). The suppression of gonadotropin 
secretion leading to failure in spermatogenesis, due to 21-hydroxylase 
was also reported (Tiitinen and Välimäki, 2002). 
1.3 Glucocorticoids: 
1.3.1 Secretion and transport: 
 Acute and chronic regulation of adrenal glucocorticoids 
synthesis is under the control of ACTH. Once synthesized cortisol 
diffuses from the adrenal corterx and binds to a specific plasma-
binding protein called transcortin, or cortisol binding globulin (CBG). 
About 90% of cortisol in the plasma is bound (Montgomery et al., 
1996). 
1.3.2 Excretion of cortisol:  
 Excretion of cortisol by the kidneys occurs in proportion to the 
concentration of unbound hormone in plasma. By measuring the 
amount of cortisol excreted in 24 hours, a test called urinary free 
cortisol, one has an index of the average free cortisol in the plasma. 
This has become one of the most accurate measures of both excessive 
and deficient cortisol states (Montgomery et al., 1996). 
1.3.3 Individual glucocorticoids: 
1.3.3.1 Cortisol (hydrocortisone)  
It is the principal naturally occurring steroid; it is given orally, a 
soluble salt can be given intravenously for rapid effect in emergency 
(Laurence et al., 1999). 
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Cortisol has one of the most pronounced circadian rhythms in 
nature. Most of the cortisol for the day is made in the few hours 
preceding awakening. For a person with a normal daily schedule, 
relatively little cortisol remains in the plasma by 4 pm. Diurnal 
variation of plasma cortisol level is related to the sleep-work pattern 
rather than to any light-dark pattern. It generally requires about 2 
weeks to alter this circadian rhythm (Montgomery et al., 1996). The 
adrenal gland produces cortisol at about 1 mg/kg B.wt. in most 
domestic species (Adams, 2001). 
1.3.3.2 Prednisolone: 
 Synthetic, predominantly anti-flammatory, biologically active, 
and has little sodium-retaining activity (Laurence et al., 1999). It is 
four times as potent as cortisol, and can be used for alternate-day 
therapy (Adams, 2001). 
1.3.3.3 Prednisone: 
 It is a prodrug i.e. it is biologically inert and converted into 
prednisolone in the liver (Laurence et al., 1999). 
1.3.3.4 Methylprednisolone: 
 It is similar to prednisolone; it is used intravenously (Laurence 
et al., 1999). 
1.3.3.5 Dexamethasone and betamethasone 
 They are longer acting than prednisolone. They are 30 times as 
potent as cortisol (Adams, 2001).  
1.3.3.6 Beclomethasone and budesonide: 
 They are used by inhalation for treating asthma (Laurence et al., 
1999). 
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 Inhaled corticosteroids are integral part of the management of 
asthma, beclomethasone dipropionate twice daily (500 µg) have 
shown decreased insulin sensitivity and significant rises in both total 
and high density lipoprotein concentration (Balfour, 1988).  Also a 
delay in puberty and growth retardation were observed in children 
(Stead and Cooke, 1989). 
1.4 Hypothalamic-pituitary adrenal axis (HPAA): 
 In most domestic species, as in humans, cortisol is the main 
glucocorticoid produced by the adrenal glands under the influence of 
ACTH with diurnal variation (Adams, 2001). 
 Glucocorticoids production is under hypothalamic control, 
corticotropin releasing hormone (CRH) is secreted by the 
hypothalamus in response to circadian rhythm, stress and other 
stimuli. CRH travels down the portal system to stimulate ACTH 
release from the anterior pituitary (Kumar and Clark, 2002).  
 Circulating ACTH stimulates cortisol production in the adrenal. 
The cortisol secreted (or any other synthetic glucocorticoid 
administered to the patient) causes negative feedback on the hypo-
thalamus and the pituitary to inhibit further CRH release (Kumar and 
Clark, 2002). Long term use of supra-physiologic doses of 
glucocorticoids may lead to adrenocortical atrophy and decreased 
adrenal secretory reserve (Adams, 2001). 
1.4.1 Physiologic stress: 
 Almost any type of physical or mental stress can lead within 
minutes to greatly enhanced secretion of ACTH and consequently 
cortisol as well, often increasing cortisol secretion as much as 20-fold 
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(Guyton and Hall, 2006). It is reported by Hamilton-Fairley and 
Taylor (2003) that tress is one of the causes of anovulation in women.   
 The association between stressful life events and the 
development of cancer is supported by a large body of anecdotal 
clinical evidence that has been collected since the eighteenth century. 
It is suggested that a prognostic association between severe life 
stressors and recurrence of breast cancer (Ramirez et al., 1989).  
1.5 Adrenal insufficiency (Addison's disease); 
 Adrenal insufficiency is common in communities with high 
prevalence of tuberculosis, but too rapid withdrawal of glucocorti-
coids is another cause (Clayton, 1989).  
 Rifampicin induces cytochrome P450 enzymes and accelerates 
the metabolism of cortisol and can cause adrenal crisis early in the 
course of antituberculous chemotherapy. Hypoglycaemia strongly 
support the diagnosis of Addison's disease (Clayton, 1989). 
 Ideal replacement therapy should mimic the adrenal glands' 
hormonal output under basal conditions, with doses increasing if the 
animal is stressed by illness or surgery. Practically, this ideal is never 
achieved (Adams, 2001). 
1.6 Cushing's syndrome: 
  It is a clinical disorder which results from the exposure of body 
tissues to sustained high blood levels of glucocorticoids (Jain, 2005).  
The syndrome is still associated with substantial morbidity and 
mortality (Boscaro et al., 2001). 
 The most common form, which is termed Cushing's disease and 
accounts for 60 – 80% of cases in most series, is generally due to 
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overproduction of ACTH from the pituitary (Boscaro et al., 2001; 
Kumar and Clark, 2002). 
 Long-term treatment with glucocorticoids (e.g. dexamethasone 
or prednisone) may produce clinical features of hypercortisolism 
(Boscaro et al., 2001).  
 The disease is characterized by truncal obesity (96%), facial 
fullness (82%), diabetes or glucose intolerance (80%), gonadal 
dysfunction (74%), acne (72%), hypertension (68%), mood disorders 
(58%) and osteoporosis (38%), in patients who suffered from 
Cushing's syndrome (Boscaro et al., 2001). In the dog iatrogenic 
Cushing's syndrome has resulted from topical ophthalmic 
glucocorticoids preparation (Murphy et al., 1990; Jeffers et al., 1991).  
 The most common cause of Cushing's syndrome is the use of 
supraphysiological amounts of exogenous glucocorticoids, including 
topical or inhaled corticosteroids (iatrogenic Cushing's syndrome). 
Thus, adequate knowledge of an individual's medication history is 
essential for diagnosis. Rarely, patient might present with factitious 
Cushing's syndrome, with hidden use of glucocorticoids, which can be 
a substantial diagnostic challenge, especially if hydrocortisone is 
being taken, since the use of this substance will cause raised 
concentrations of circulating cortisol (Newell-Price et al., 2006). 
 New data, suggest that Cushing's syndrome is more common 
than had previously been thought. In screening studies of obese 
patients with type 2 diabetes, especially those with poor blood glucose 
control and hypertension, the reported prevalence of Cushing's 
syndrome is between 2 and 5%. These data suggest that more 
widespread screening for Cushing's syndrome in such patients is 
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warranted. Researchers still need to prove that control of cortisol 
excess is more beneficial than the attention to more specific 
abnormalities of metabolic and cardiovascular risk. Biochemical 
confirmation of the hypercortisolaemic state must be established 
before any attempt at differential diagnosis: failure to do so will result 
in misdiagnosis, inappropriate treatment and poor management 
(Newell-Price et al., 2006). Diabetes mellitus and hyperadrenocortism 
are both well documented and commonly recognized endocrinopathies 
of dogs (Blaxter and Gruffyad-Joes, 1991). 
         Reproductive abnormalities frequently associated with Cushing's 
syndrome in the dog. Moreover a substantial reductions in basal levels 
of T4 and T3 have been observed in  human patients with Cushing's 
syndrome (Kemppainen et al., 1983). 
1.7 The thyroid gland:  
In the normal adult, the thyroid gland weight is about 25 g and 
consists of two connected lobes, closely associated with the trachea. 
The gland is divided by connective tissue into clusters of follicles or 
acini. Each follicle consists of a single layer of cells surrounding a 
colloid containing the protein thyroglobulin; there are about a million 
follicles in the human gland. This colloidal thyroglobulin is the source 
of the two thyroid hormones: thyroxine (T4) and triiodothyronine (T3) 
(Gillham et al., 2001).  
1.7.1 Thyroid hormones:  
Thyroid hormones are vital signaling molecules in both highly 
develop and primitive organisms. In-contrast to many signals that 
fluctuate with relative rapidity, the signals of thyroid hormones are 
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remarkably stable as a result of the long half-life (6 to 9 days) of T4. 
On the other hand T3 is more active than T4 and has a half-life of 24 to 
36 hours (Montgomery et al., 1996). 
Thyroid hormones regulate energy and heat production; 
facilitate healthy development of the central nervous system, somatic 
growth and puberty; and regulate synthesis of protein important in 
hepatic, cardiac, neurological and muscular function. These diverse 
effects account for numerous and varied symptoms of hyper-
thyroidism (Cooper, 2003). 
1.7.2 Biosynthesis of T4 and T3:  
 Iodide absorbed from the diet or drinking water is transported in 
the blood to the thyroid gland, where it is very efficiently transferred 
into the follicular cells of the thyroid gland by an 'iodide pump' system 
which is dependant on ATP (Gillham et al., 2001). The first step in 
synthesis of thyroid hormone is the accumulation of iodine 
(Montgomery et al., 1996). 
 The next step in thyroid hormone synthesis involves the 
covalent attachment ("Organification") of the iodine to thyroglobulin 
(Montgomery et al., 1996). Thyroglobulin is a typical secretory 
protein. The vesicles segregate to the apical plasma membrane of the 
follicular cells and it is this stage that thyroglobulin undergoes 
iodination prior to its release and storage in the colloid (Gillham et al., 
2001). Iodide is oxidized by hydrogen peroxide to form a positively 
charged iodine ion that reacts with specific tyrosine residues on the 
thyrogloulin to produce monoiodotyrosines within the thyroglobulin. 
This reaction is catalyzed by the enzyme thyroperoxidase.          
Monoodotyrosines undergo a similar second reaction to form 
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diiodotyrosine. This reaction is also catalyzed by thyroperoxidase 
(Montgomery et al., 1996). 
 After this step comes the coupling of iodotyrosines to form the 
thyroid hormones. The coupling of two 3/5 diiodotyrosines yields T4, 
and the coupling of 3 monoiodotyrosine to diiodotyrosine forms T3 
with the removal of alanine side chain (Montgomery et al., 1996). 
 Under normal conditions, T4 makes up the majority of 
hormones produced by the thyroid gland, relatively little T3 is 
synthesized. Instead, most T3 in plasma is formed in extrathydroidal 
tissue by 5′-deiodinase, which catalyzes the removal of an iodine from 
the outer ring of T4. Many tissues also have the enzyme 5-deiodinase 
which catalyzes the removal of an iodine from the inner ring to form 
reverse T3 (rT3), which is an inactive compound. Formation of rT3 is 
thought to be an adaptive mechanism to lower the basal metabolic rate 
during starvation or systemic illnesses (Montgomery et al., 1996). 
1.7.3 Release of T4 and T3 from the thyroid gland: 
 Thyroglobulin itself is not released into the circulating blood in 
measurable amounts; instead, T4 and T3 must first be cleaved from the 
thyroglobulin molecule and then these free hormones are released. 
This process occurs as follows: The apical surface of the thyroid cells 
sends out pseudopod extensions that close around small portions of 
the colloid to form pinocytic vesicles that enter the apex of the thyroid 
cell, then lysosomes in the cell cytoplasm immediately fuse with these 
vesicles to form digestive vesicles containing digestive enzymes from 
the lysosomes mixed with the colloid. Multiple proteases among the 
enzymes digest the thyroglobulin molecules and release T4 and T3 in 
free form. These then diffuse through the base of the thyroid cells into 
 14
the surrounding capillaries. Thus, the thyroid hormones are released 
into the blood (Guyton and Hall, 2006). 
 About three quarters of the iodinated tyrosine in the 
thyroglobulin never become thyroid hormones but remains 
monoiodotyrosine and diiodotyrosine. During the digestion of the 
thyroglobulin molecule to cause release of T4 and T3, the iodinated 
tyrosines also are freed from the thyroglobulin molecules. However, 
they are not secreted into the blood. Instead, their iodine is cleaved 
from them by a deiodinase enzyme that makes virtually all this iodine 
available again for recycling within the gland for forming additional 
thyroid hormones. In the congenital absence of this deiodinase 
enzyme, many persons become iodine-deficient because of the failure 
of this recycling process (Guyton and Hall, 2006). 
1.7.4 Control of thyroid hormones secretion: 
 Stimulation of follicle cells by thyroid stimulating hormone 
(TSH) activates a cAMP-dependant response which leads to the 
reuptake of the iodinated thyroglobulin from the colloid by a process 
of pinocytosis. The pinocytotic vesicles then fuse with lysosomes 
where proteolysis of the protein occurs to release T3 and T4 (Gillham     
et al., 2001).  
 The secretion of thyroid hormones is controlled by the pituitary 
gland and the hypothalamus. Thyrotropin-releasing hormone (TRH), 
secreted by the hypothalamus, stimulates secretion of TSH by the 
pituitary gland. TSH, in turn stimulates the secretion of T4 and T3 
(Evinger and Nelson, 1984). 
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1.7.5 Thyroid diseases: 
 Diseases of the thyroid gland are a common type of endocrine 
dysfunction. They may be as an excess of thyroid hormones, called 
thyrotoxicosis or hyperthyroidism, or as lack of thyroid hormones, 
called hypothyroidism (Montgomery et al., 1996). 
1.7.5.1 Hyperthyroidism:  
 It is a common disease in young women. It is usually caused by 
an immune alteration that leads to the production of auto-antibodies 
called, thyroid-stimulating immunoglobulins (TSIG). These antibodies 
are capable of binding to the TSH receptor and stimulating adenyl 
cyclase. The thyroid gland is stimulated both to produce thyroid 
hormones and to grow, but the thyroid hormone T4 (or T3)  produced 
is not capable of shutting off the production of the TSIG. No negative 
feedback occurs. Hyperthyroidism can occasionally be caused by 
tumors or autonomously functioning nodules of the thyroid gland 
(Montgomery et al., 1996). 
 Hyperthyroid patients manifest symptoms of increased 
metabolism, including weight loss despite an augmented appetite, heat 
intolerance, rapid heart rate, tremors, and nervousness. The plasma 
levels of the thyroid hormones are elevated, but levels of TSH are 
suppressed because T4 and T3 inhibit pituitary synthesis and release of 
TSH. Hyperthyroidism caused by elevated TSIG level is called 
Graves' disease and is often associated with goiter and protuberance of 
the eyes (Montgomery et al., 1996). This Graves' disease is treated 
with methylprednisolone (Dandona et al., 1989) and this predisposes 
individuals to glucocorticoid adverse effects. 
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1.7.5.2 Hypothyroidism: 
 Normal secretion of thyroid hormone depends on the intact 
feedback loop of the hypothalamic-pituitary-thyroid axis. Hypo-
thyroidism is the term for deficient thyroid hormones secretion by the 
thyroid gland (Lindsay and Toft, 1997).  
 Thyroid hormones have an important role in intellectual 
development which makes screening programmes essential. Un-
treated, the hypothyroid newborn infant will lose an estimated 3 – 5 
IQ points every month for the first 6 – 16 months (Lindsay and Toft, 
1997).  
 Primary hypothyrodism is the most common form, and implies 
dysfunction of the thyroid gland. Secondary hypothyroidism results 
from dysfunction of the pituitary gland with resultant inability to 
secrete TSH. Histological evaluation of a thyroid gland biopsy 
specimen reveals lack of active resorption of colloid. Tertiary 
hypothyroidism involves dysfunction of the hypothalamus with 
impaired secretion of the thyroid releasing hormone. Histological 
evaluation of thyroid tissue should resemble secondary 
hypothyroidism (Evinger and Nelson, 1984).   
 There are several factors that may alter the basal plasma thyroid 
hormone concentration (e.g. corticosteroids) and result in an erroneous 
assessment of thyroid gland function (Evinger and Nelson, 1984).  
 It is emphasized that both secondary and tertiary hypo-
thyroidism are rare, although important to diagnose; the pattern of 
subnormal T4 and thyrotropin is more likely to be due to non-thyroidal 
illness, than to either of these disorders (Lindsay and Toft, 1997). 
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 In-contrast to hyperthyroid patients, patients with hypo-
thyroidism have a lowered metabolic rate. They are usually cold and 
gain weight despite normal or diminished caloric intake and may be 
more susceptible to over dosage of medications because they 
metabolize them slowly. Severely hypothyroid patients become 
hypothermic, sluggish, and lapse into unconsciousness, a state called 
myxedema coma. If untreated, myxedema coma is fatal (Montgomery 
et al., 1996). 
1.8 The luteinizing hormone (LH): 
 The gonads (testes and ovaries) synthesize hormones necessary 
for physical development and reproduction. A single hypothalamic 
releasing factor, gonadotropin-releasing hormone (GnRH), stimulates 
the anterior pituitary to release the glycoproteins, luteinzing hormone 
and follicle-stimulating hormone (FSH). LH stimulates the testes to 
produce androgens and ovaries to produce estrogens and progesterone. 
FSH regulates the growth of ovarian follicles and stimulates testicular 
spermatogenesis. For maximum effect on the male or female gonad, 
FSH also requires the presence of LH (Champe and Harvey, 1994). 
 The ovarian changes that occur during the sexual cycle depend 
completely on the gonadotropic hormones, FSH and LH. In the 
absence of these hormones, the ovaries remain inactive, which is the 
case throughout childhood when almost no pituitary gonadotropic 
hormones are secreted (Guyton and Hall, 2006). 
 As shown in Fig. (2) LH is necessary for final follicular growth 
and ovulation. Without this hormone, even when large quantities of 
FSH are available, the follicle will not progress to the stage of 
ovulation. The LH also has a specific effect on the granulosa and 
 18
theca cells, converting them mainly to progesterone-secreting cells. 
Therefore, the rate of secretion of estrogen begins to fall about 1 day 
before ovulation, while increasing amounts of progesterone begin to 
be secreted. It is in this environment of rapid growth of the follicle, 
diminishing estrogen secretion (after a prolonged phase of excessive 
estrogen secretion) and initiation of secretion of progesterone that 
ovulation occurs. Without the initial pre-ovulatory surge of LH, 
ovulation will not take place (Guyton and Hall, 2006). 
If the pre-ovulatory surge of LH is not of sufficient magnitude, 
ovulation will not occur and the cycle is said to be "anovulatory" and 
there is almost no secretion of progesterone during the later portion of 
the cycle (Guyton and Hall, 2006).  
 The first cycles after the onset of puberty are usually 
anovulatory, as are the cycles occurring several months to years 
before menopause presumably because the LH surge is not potent 
enough at these times to cause ovulation (Guyton and Hall, 2006).  
 It has long been known that administration of either estrogen or 
progesterone "the pill", if given in appropriate quantities during the 
first half of the monthly cycle, can inhibit ovulation. Because these 
hormones can prevent the preovulatory surge of LH secretion by the 
pituitary gland, which is essential for causing ovulation (Guyton and 
Hall, 2006). 
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Fig. (2): Changes in the levels of gonadotropic hormones and 
ovarian hormones during the menstrual cycle (from Jain, 
2005). 
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 Testosterone is the major sex steroid in men, it is produced by 
Leyding cells of the testes. The major stimulus for synthesis and 
secretion of testosterone is LH, which binds to specific receptor on the 
surface of Leyding cells, stimulating the production of cyclic AMP. 
This results in a cascade of events that culminates in an increase in 
SCC enzyme, 17 α-hydroxylase and 17, 20-Lyase activities. Testo-
sterone is present in very high concentration in the testes, and such 
concentration is necessary for normal spermatogenesis (Montgomery 
et al., 1996). The amount of testosterone secreted increases 
approximately in direct proportion to the amount of LH available 
(Guyton and Hall, 2006). 
Mature Leyding cells are normally found in a child's testes for a 
few weeks after birth but then disappear until after the age of about 10 
years. However, either injection of purified LH into a child at any age 
or secretion of LH at puberty cause testicular interstitial cells that look 
like fibroblasts to evolve into functioning Leyding cells (Guyton and 
Hall, 2006).  
1.9 Adverse effect of glucocorticoids: 
 Exposure to excessive glucocorticoids causes so many adverse 
effects: Adrenocortical suppression was reported by Newton et al. 
(1978) in workers manufacturing synthetic glucocorticoids (in spite of 
their adherence to the safety precautions), invasive fungal infection 
(Lionakis and Kontoyiannis, 2003), growth retardation in asthmatic 
children (Balfour, 1988), osteoporosis (Shewring et al., 1991; Spector, 
1993), cataract (Kumar and Clark, 2002), obesity (Haslam and James, 
2005), hypertension and glucose intolerance (Newell-Price et al., 
 21
2006) and others mentioned below to reveal the hazards of using 
glucocorticoids.  
1.9.1 Effects of glucocorticoids on the thyroid gland: 
 Six men were given a single dose of 8 mg betamethasone 
intravenously (1/v). Immediately after the l/v administration of 
betamethasone, both plasma TSH and cortisol levels began to fall, and 
there was a significant reduction of TSH after 12 hr. There were 
significant decrements in plasma T3 levels 16 to 40 hr. after 
betamethasone administration, while plasma T4 levels didn't show any 
significant changes. Although the hypothesis that peripheral 
conversion of T4 to T3 is selectively inhibited by the glucocorticoids is 
intriguing, some of the T3 decrement may have resulted from the 
suppression of TSH which is known to induce the thyroidal secretion 
of T3 in preference to T4. This data indicate that the effects of a single 
injection of a large dose of synthetic corticosteroid persist for at least 
5 days. Therefore, in clinical situation, measurement of plasma thyroid 
hormones, TSH and cortisol should be avoided at least a week after 
such treatment (Azukizawa et al., 1979). 
 In another study in dogs, the effect of multiple intramuscular 
injections of prednisone (2.2 mg/kg Bwt) every alternate day on 
thyroid morphology and plasma thyroxine and triiodothyronine 
concentrations were investigated. Plasma T4 and T3 concentrations 
decreased significantly after 3 injections of prednisone were made. 
The reduced basal plasma T4 and T3 values in dogs given multiple 
prednisone treatments were similar to reduction in circulating 
iodothyronines levels after glucocorticoids administration in persons 
and rats (Woltz et al., 1983). 
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 In-contrast, a single injection of prednisone did not significantly 
reduce plasma T4 concentration. The significant reduction in plasma 
T3 values when plasma T4 values were non-significantly reduced 
implies that prednisone either inhibited thyroid secretion of T3 or 
inhibited the conversion of T4 to T3. It has been proposed that 
glucocorticoids specifically inhibit the 5' deiodinase enzyme which 
function to convert T4 to T3 in the periphery (Wotz et al., 1983). 
 The impairment of thyroid function due to prednisolone 
administration is confirmed by morphologic examination of the gland. 
Indeed, inactive areas characterized by enlarged follicles with 
accumulation of colloid droplets in epithelial cells were frequently 
observed in thyroids of treated dogs (Kurtdede et al., 2004). The 
remarkable low number of lysosomes in thyroids from treated dogs 
suggested that the inhibition of the lysosomal hydrolysis of colloids in 
follicle cells induced severe decrease of the hormone release into the 
blood (Kemppainen et al., 1983; Woltz et al., 1983; Kurtdede et al., 
2004). Furthermore, previous studies in humans have reported that 
steroid anti-inflammatory drugs such as prednisolone directly acted   
on hypothalamo-hypophyseal axis by reducing the hypophyseal 
hormones, and notably of TSH and consequently by inducing a 
secondary hypothyroidism (Kurtdede et al., 2004). 
 The repeated administration of the synthetic glucocorticoid, 
prednisone was clearly associated with substantial reduction in basal 
levels of T4 and T3. Similar reduction in the levels of both hormones 
have been observed in human patients who suffered from Cushing's 
syndrome (Visser and Lamberts, 1981).  
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It is suggested that glucocorticoids induced suppression of T4 
and T3 levels is a dose-related phenomenon, which may also be 
affected by the route of administration and the chemical form of the 
agent (Kemppainen et al., 1983; Woltz et al., 1983).  
1.9.2 Effects of glucocorticoids on gonadotrophic hormones 
secretion: 
 Short term high dose of dexamethasone administration 
decreases basal serum levels of LH and FSH in women with normal 
menstrual cycles (Sowers et al., 1979). In another study it was 
observed that administration of paramethasone acetate 5 mg daily to 
young women with normal menstrual cycles resulted in significantly 
depressed basal LH levels on the second day of administration and 
that this suppression persisted throughout most of the menstrual cycle 
(Cortis-Gallegos et al., 1975).  
 Not only did short-term administration of high doses of 
dexamethasone suppress basal levels of LH and FSH, but also the 
gonadotropin response to GnRH was blunted. It has also been reported 
that women on long-term glucocortioid therapy had significantly 
lower LH responses to GnRH than female controls receiving no 
glucocorticoids. The authors of that study interpreted their results as 
indicating that glucocorticoids suppress LH release at the anterior 
pituitary level by diminishing responsiveness to GnRH (Sowers et al., 
1979; Insler and Lunenfeld, 1994). 
 It has been observed that patients with Cushing's disease have 
suppressed basal level of LH and FSH (Luton et al., 1977). 
Furthermore pregnancy is a rare occurrence in women with Cushing's 
syndrome as a result of suppression of gonadotropin secretions 
primarily by excess glucocorticoids (Aron et al., 1990).  
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 Continuous infusion of intact heifers with ACTH beginning on  
day 2 of the estrous cycle was able to inhibit the small spikes in 
plasma LH that normally occur on day 3 and 4. The depression of 
plasma progesterone is probably due to insufficient circulating LH 
which resulted in an incomplete development and/or function of 
corpus luteum. It was also demonstrated that implantation of 
dexamethasone into the preoptic area was as effective as systemic 
injections in blocking ovulation in rats (Li and Wagner, 1983). 
 The effect of glucocorticoids on gonadal steroid and 
gonadotropic hormone concentrations and subsequent follicular 
activity in cows undergoing normal estrous cycle was evaluated by 
administration of dexamethasone (DXM) during the middle of the 
luteal phase using 2 mg 1/M of DXM twice daily from day 13 through 
day 17. Results indicated that high glucocorticoid concentrations in 
the middle of the cycle may delay the onset of the next estrus. This 
delay appears to be attributable to prolonged luteal activity that may 
be associated with reduction in pulsatile estradiol secretion as a 
consequence of suppressed LH concentration in the middle of the 
cycle. Administration of DXM during the follicular phase delays or 
interferes with ovulation in cows (Vighio and liptrap, 1990).  
 When bulls were given 20 mg DXM (I/M), the concentration of 
LH and testosterone were significantly (P< 0.001) lower in the treated 
group compared to the control on day 2 of the experiment. DXM is a 
very potent depressant of the levels of both testosterones and LH in 
bovine plasma and probably acts through pituitary responsiveness to 
GnRH (Chantaraprateep and Thibier, 1978). 
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 LH secretion in dogs is inhibited by prednisone administration, 
which consequently results in reduced testosterone concentration 
(Kemppainen et al., 1983).  
1.9.3 Effect of glucocorticoids on the liver:   
 Healthy dogs were given 1 ml of an otic product containing 
dexamethasone administered twice daily to both ears of each dog for 
21 days. Increase in alkaline phosphatase (ALP), γ-glutamyl 
transferase (GGT) and alanine transaminase (ALT) activity was 
progressive until day 21. GGT, ALP and ALT activity increased 58-
fold, 11-fold and 18-fold, respectively (Meyer et al., 1990). Dogs 
given ophthalmic medications containing glucocorticoids have had 
abnormal liver test results and adrenal suppression (Zenoble et al., 
1987; Glaze et al., 1988). Seemingly, glucocorticoids are absorbed 
from the ear canal of dogs, and even small amounts of glucocorticoids 
in contact with a limited surface area result in multi-system effects. 
Unfortunately, results of ALP and GGT are used as sensitive indicator 
of cholestatic disorders (Meyer et al., 1990). Prednisone injections of 
4 mg/kg B.wt./day given for dogs resulted in hepatomegaly due 
primarily to hepatocellular accumulation of glycogen (Fittschen and 
Bellamy, 1984). 
 Serum ALP, ALT and GGT activities increased significantly  
(P< 0.05) in all dogs subjected to hepatic duct legation and those 
treated with dexamethasone (DeNovo and Prasse, 1983).  
1.9.4 Effect of glucocorticoids on the pancreas: 
 Thirty seven patients with acute severe Graves' ophthalmopathy 
were treated with methylprednisolone infusions. There were consistent 
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subclinical side effects, which consist of an increase in serum activity 
of exocrine pancreatic enzymes trypsin, amylase and lipase after 
methylprednisolone treatment (Dandona et al., 1989). This is 
suggestive of pancreatitis (Dandona et al. 1985; Dandona et al., 1989; 
Kumar and Clark, 2002).  
1.9.5 Effect of glucocorticoids on blood glucose concentration: 
 Glucocorticoids stimulate gluconeogenesis and cause a 
moderate decrease in the rate of glucose utilization by most of the 
cells in the body. These cause the blood glucose to rise. The rise in 
blood glucose in turn stimulates secretion of insulin. The increase 
plasma levels of insulin, however, are not as effective in maintaining 
plasma glucose as they are under normal conditions. Glucocorticoids 
reduce the sensitivity of many tissues, especially skeletal muscles and 
adipose tissue to the stimulatory effects of insulin on glucose uptake 
and utilization (Guyton and Hall, 2006). 
 The increase in blood glucose concentration is occasionally 
great enough (50% or more above normal) that the condition is called 
adrenal diabetes. Administration of insulin lowers the blood glucose 
concentration only to a moderate amount in adrenal diabetes – not 
nearly as much as it does in pancreatic diabetes – because the tissues 
are resistant to the effects of insulin (Guyton and Hall, 2006).  
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CHAPTR TWO 
MATERIALS AND METHODS 
 
2.1 Experimental animals: 
 Ten adult intact males, domestic rabbits (Lepus cuniculus) 
ranging in weight from 1.1 – 1.65 kg were used in this study. The 
animals were purchased from the local market and they were in good 
health.  
2.2 Housing and management:  
2.2.1 Housing:  
The animals were brought to the Department of Biochemistry, 
Faculty of Veterinary Medicine, Khartoum University, where they 
were kept in a calm room, provided with adequate ventilation under 
natural light. The rabbits were penned singly in wire net cages (60 x 
60 x 60 cm) to avoid social stress (Szeto et al., 2004) and because 
intact bucks fight and inflict severe injuries (Flecknel, 2000). They 
were kept for an adaptation period of two weeks before 
experimentation so that they were accustomed to handling, collection 
of blood and experimental conditions.  
2.2.2 Feeding: 
 The animals were fed equal amounts of fresh Lucerne 
(Medicago sativa) 0.4 kg and sorghum grains (Sorghum vulgare 
cundatum) 90 g with water available ad lib. 
 
 
 
 28
2.2.3 Hygiene: 
 The cages were cleaned everyday using soap and water to avoid 
high ammonia levels that predispose to respiratory infections. Black 
phenolic plus water were used for cleaning during the experimental 
period, to disinfect the whole area. 
2.2.4 Clinical examination: 
 The animals were daily examined and they remained healthy 
throughout the study. 
2.3 The experimental procedure: 
2.3.1 Animals grouping: 
 The rabbits were randomly assigned into treated and control 
groups (five rabbits per group). 
2.3.2 The treated group: 
 This group was given prednisolone 1% (VMD, Belgium); 2.2 
mg/kg body weight (Bwt) intramuscularly 1/M (occipital muscle) 
every other day at 9 a.m. using one ml syringe of 28 needle gauge, for 
a total of 6 doses. Day 1 of the experiment is referred to the day of the 
first injection. 
2.3.3 The control group: 
  This group was given an equivalent volume of prednisolone 1% 
- vehicle solution 1/M (occipital muscle), which was obtained from 
(VMD Belgium) via the express mail. 
2.3.4 Handling and restraint:  
 Animals were approached vertically (from above), grasping by 
the 'scruff' of the withers to lift the animal from the cage, supporting 
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the rump with the other hand. The rabbit was then placed in a small 
plastic cage so that it was confined and easily injected.  
2.3.5 Blood sampling:   
 The hair over the jugular vein was shaved. Blood for separation 
of serum was obtained by venipuncture of the jugular vein using 24 
gauge needle and 5 ml disposable syringe. Blood was then transferred 
to plain tubes with clot activator and allowed to clot at room 
temperature for 3 hours. The clotted blood was centrifuged at 3000 
rpm for ten minutes. The separated serum was decanted using a 
micropipette and immediately stored at -20oC until analysis.  
2.4 Analytical methods: 
2.4.1 Stat Fax 2100 Micro- plate Reader (USA): 
 It is fully automatic, reads and prints absorbance of 96 wells in 
about 2 minutes. It has a large non-volatile memory stores at least 50 
user entered test, light source is tungsten lamb with lamb saver 
feature. Calculation modes includes; single-point calibration, uptake 
mode, point to point curve fit, polynomial regression linear regression, 
cut off absorbance and multipoint % absorbance. Additional features 
includes: complete user prompting flags and error massager, 
automatic interpretation options, control locator, self-check system 
and curve plotting and editing.  
2.4.2 Determination of serum thyroxine (T4) concentration using 
enzyme immunoassay (EIA): 
Principle of the test: 
 Monoclonal antibodies specific to T4 are immobilized on micro 
well plates. The label used is T4 conjugated to horseradish Peroxidase 
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(HRP). In the assay T4 is released from its binding proteins by ANS 
(8-Anilinonaphalen-1-sulfonic acid) present in the assay buffer. Total 
T4 in the specimen competes with HRP-labeled T4 for binding to the 
immobilized antibody. After washing, enzyme substrate is added. The 
amount of total T4 in the sample is inversely proportional to the 
enzyme activity. The reaction is terminated by adding the stop 
solution. Absorbance is measured on a plate reader. 
Reagents: 
- Micro-well plate: 
12 strips x 8 breakable wells coated with mouse monoclonal T4 
antibody. 
- Assay buffer 
 It contains Kathon (0.09%) as preservative. 
- Standards (A, B, C, D, E, F). 
 The standard values are 0, 20, 50, 100, 200 and 300 nmol/l. 
- Enzyme conjugate 
 T4 conjugated to horseradish Peroxidase. 
- Wash solution. 
- TMB substrate. 
- Stop solution 
 It contains 0.3 M H2SO4. 
Equipment: 
- Pipette with disposable plastic tips  
50 µl (standards samples). 
- Multi-channel pipette with disposable plastic tips 
 50 – 100 µl (conjugate substrate, stop solution). 
- Timer. 
- Stat Fax 2100 micro-plate reader. 
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- Aspiration device.  
Test procedure: 
- All reagents were allowed to reach room temperature before use. 
- The wells to be used on the plate were marked. 
- 50 µl of the standards (in duplicate) and serum samples were 
pipetted into appropriate wells. 
- 50 µl of diluted enzyme conjugate were dispensed into the wells. 
- The plate was covered and shaken for a few seconds to mix the 
contents of the wells, then incubated for 60 minutes at room 
temperature in the dark.  
- The wells were aspirated and washed 3 times with 300 µl of washing 
solution. 
- 100 µl of TMB-substrate solution were added into each well (at 
timed intervals). 
- The plate was covered and incubated for 15 minutes at room 
temperature in the dark. 
- The reaction was stopped by adding 100 µl of stop solution into each 
well at the same timed intervals above, the plate was shaken gently 
to mix the solutions. 
- The absorbance was measured at 450 nm.  
Calculation of the results: 
- The mean absorbance for each duplicate was calculated. 
- Standard curve system was plotted and the concentration of T4 in the  
samples was calculated. 
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2.4.3 Determination of serum triiodothyronine (T3) concentration 
using EIA: 
Principle of the test: 
Micro-plates are coated with anti-T3 antibodies. Upon mixing 
immobilized anti-T3 antibodies, enzyme-T3 conjugate, and serum 
containing the native T3 antigen, a competition reaction results 
between the native T3 and the enzyme-T3 conjugate for a limited 
number of insolubilized binding sites. After equilibrium was attained, 
the antibody-bound fraction is separated from unbound antigen by 
decantation or aspiration. The activity of the enzyme present on the 
surface of the well is quantified by reacting with a suitable substrate to 
produce color. The enzyme activity in the antibody-bound fraction is 
inversely proportional to the native antigen concentration. By utilizing 
several different serum references of known antigen concentration, a 
dose response curve can be generated from which the antigen 
concentration of unknown can be ascertained. From comparison to the 
dose response curve, an unknown specimen's activity can be 
correlated with total triiodothyronine concentration.  
Reagents: 
- Micro-well plate: One 96-well micro plate coated with sheep anti-
triiodothyronine serum. 
- Enzyme conjugate: Triiodothyronine-horseradish perxidase (HRP) 
conjugate in a bovine albumin-stabilizing matrix. 
- Conjugate diluents: One bottle containing buffer, red dye. MIT (150 
mg/l) and BND (150 mg/dl) preservatives, and biding 
protein inhibitors. 
- Standard curve: Six vials at concentration of 0, 50, 100, 250, 500 and 
750 ng/dl. 
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- Wash solution: One vial contains a phosphate buffer and a detergent 
(Tween 20). 
TMB-substrate: One bottle containing tetrametylbenzidine (TMB) in 
buffer. 
- Stop solution: It contains 0.3 M H2SO4. 
Equipment: 
- 50 µl pipette 
- Dispensers for repetitive deliveries of 0.100 ml and 0.003 ml 
volumes. 
- Micro-plate washer (squeeze bottle). 
- Stat Fax 2100 Micro-plate Reader. 
- Absorbent paper for blotting the micro-plate wells. 
- Timer. 
Test Procedure: 
- All reagents, serum references and controls were brought to 
room temperature. 
- The micro-plate wells were assigned for each serum reference, 
control and specimen to be assayed in duplicate. 
- 50 µl of the appropriate serum reference, or specimen were put 
into the assigned wells. 
- 100 µl of triiodothyronine-enzyme conjugate solution were 
added to all wells.  
- The micro-plate was swirled for 20 – 30 seconds and then 
incubated for 60 minutes. 
- The contents of the micro-plate were decanted and the plate was 
blotted dry with absorbent paper. 
- 300 µl of wash buffer were added and then decanted (two 
times). 
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- 100 µl TMB-substrate were added to all wells and then 
incubated for 15 min. at room temperature. 
- 100 µl of the stop solution were added to each well. 
- The absorbance was read in each well at 450 nm. 
Results: 
 A dose response curve is used to ascertain the concentration of 
triiodothyronine in unknown specimens. 
2.4.4 Determination of serum thyroid stimulating hormone (TSH) 
using EIA: 
Principle of the test: 
 Antibody specific to TSH molecule is immobilized on micro-
well plates and other antibodies to the TSH molecule are conjugated 
with biotin. TSH from the sample is bound to the plates and biotin 
conjugate is added. After a washing step, streptavidin horseradish 
peroxidase (HRP) conjugate is added. After a second washing step, 
substrate is added. The enzymatic reaction is proportional to the 
amount of TSH in the sample. The reaction is terminated by adding 
the stop solution, absorbance is measured on a plate reader at 450 nm. 
Equipment: 
- Pipette with disposable plastic tips 10 – 50 µl (standards 
samples). 
- Multi-channel pipette with disposable plastic tips: 100 µl 
- Aspiration device. 
- Stat Fax 2100 Micro-plate Reader. 
Reagents: 
- Micro-well plate coated with anti TSH antibody. 
- Assay buffer containing thimerosol 0.02% and gentamycin as 
preservatives. 
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- Standards, standards values are 0, 1, 6.5, 20 and 50 mlU/L. 
- Biotin conjugate antibodies labeled with biotin. 
- Streptavidin HRP conjugate. 
- Wash solution. 
- TMB substrate. 
- Stop solution. 
Test procedure: 
- All reagents were allowed to reach room temperature before 
use. 
- The wells to be used were marked. 
- 100 µl of biotin conjugate were pipetted into the wells. 
- 50 µl of standards in duplicate and serum samples were pipetted 
into appropriate wells, then incubated for 60 minutes at room 
temperature. 
- The wells were washed 5 times with 300 µl of washing 
solution. 
- 100 µl of diluted streptavidin HRP conjugate were pipetted into 
the wells. 
- The wells were washed again 5 times with 300 µl of washing 
solution. 
- 100 µl of TMB substrate solution were added at timed intervals 
into each well. The plate was covered and incubated for 20 
minutes at room temperature. 
- The reaction was stopped by adding 100 µl of stop solution into 
each well at the same timed intervals as above. Then the plate 
was mixed. 
- The absorbance was measured at 450 nm. 
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Calculation of the results: 
- The mean absorbance for each duplicate was calculated. 
- The absorbance value of the zero standard was subtracted from 
the mean absorbance values of standards, control and samples. 
- Standard curve was drawn and the TSH concentrations of the 
samples were read.  
2.4.5 Determination of serum luteinizing hormone (LH) using EIA 
Principle of the test: 
 The LH assay is based on simultaneous biding of LH to two 
monoclonal antibodies, one immobilized on micro-well plates, the 
other conjugated with horseradish  peroxidase (HRP). After a washing 
step, enzyme substrate is added. The enzymatic reaction is 
proportional to the amount of LH in the sample. The reaction is 
terminated by adding the stop solution. Then absorbance is measured 
on a plate reader. 
Reagents: 
- Micro-well plate: breakable wells coated with LH antibody. 
- Assay buffer. 
- Standard curve lyophilized. The standard values are 0, 1, 2.5, 
10, 40 and 100 iu/L. 
- Enzyme conjugate: LH antibody conjugated with horseradish 
peroxidase. 
- Wash solution. 
- TMB substrate. 
- Stop solution 0.3 M H2SO4. 
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Equipment: 
- Pipette with disposable plastic tips 25 µl (standard samples). 
- Multi-channel pipette with disposable plastic tips. 
- Aspiration device. 
- Timer. 
- Stat Fax 2100 micro-plate Reader. 
Test procedure: 
- All reagents were allowed to reach room temperature before use 
and the standards were reconstituted. 
- The wells to be used were marked on the plate. 
- 25 µl of the assay buffer were pipetted into the wells. 
- 25 µl of the standards and serum samples were pipetted into 
appropriate wells. 
- 25 µl of enzyme conjugate were pipetted into the wells, the 
plate was covered and incubated for 60 minutes at room 
temperature. 
- The wells were aspirated and washed 3 times with 300 µl of the 
washing solution. 
- 100 µl of TMB substrate were added to each well at timed 
intervals. 
- The plate was covered and incubated for 15 minutes at room 
temperature. 
- The reaction was stopped by adding 100 µl of stop solution to 
each well at the same timed intervals as above. 
- The absorbance was measured at 450 nm. 
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Calculation of the results: 
- The mean absorbance for each duplicate was calculated. 
- Standard curve was made, and the concentration of LH in the 
samples was calculated. 
2.5 Statistical analysis: 
 Two groups compared test (t-test) was used for statistical 
analysis of data (Gomez and Gomez, 1984) with the aid of statistical 
package for social science programme (SPSS). 
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CHAPTER THREE 
RESULTS 
 
        Mean concentrations of serum thyroxine (T4), triiodothyronine 
(T3), thyroid stimulating hormone (TSH) and luteinizing hormone 
(LH) in rabbits given multiple I/M injections of prednisolone (2.2 
mg/kg Bwt) every alternate day, were compared with those of control 
animals in two separate periods, day 6 and day 12 respectively. 
3.1 Concentration of serum thyroxine (T4): 
 The concentrations of T4 on day 6 and day 12 of the experiment 
were presented in Table (1) and Fig. (3).  
On day 6 of the experiment there was non-significant difference 
in serum T4 levels between the treated (106.4 ± 14.2) and the control 
groups (105.2 ± 5.9). 
 On day 12 the mean value of T4 was significantly (P< 0.05) 
reduced in the treated group (96.2 ± 4.1) compared to the control 
(129.0 ± 5.4). 
3.2 Concentration of serum triiodothyronine (T3): 
 The concentrations of T3 on day 6 and day 12 of the experiment 
were presented in Table (1) and Fig. (4).  
On day 6 the mean value of the treated group (283 ± 28.4) was 
non-significantly lower than that of the control group (304 ± 34). 
 On day 12 there was a highly significant (P< 0.05) decrease in 
serum T3 values of the treated group (272 ± 24.8) compared to the 
control (342.6 ± 47.3). 
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Table (1): The levels of thyroxine (T4), triiodothyronine (T3), thyroid 
stimulating hormone (TSH) and luteinizing hormone (LH) 
in rabbits treated with prednisolone (2.2 mg/kg Bwt) given 
I/M compared to the control on day 6 and day 12.  
 
Day 6 Day 12  Hormone 
Control Treated Control Treated 
T4 nmol/l 106.4±14.2a 105.2±5.9a 129.0±5.4a 96.2±4.1b 
T3 ng/dl 304.0±34.0a 283.4±28.4a 342.6±47.3a 272.0±24.8b 
TSH miu/l 0.24±0.1a 0.206±0.08a 0.17±0.05a 0.14±0.03a 
LH miu/l 11.0±0.22a 5.74±2.2b 13.9±3.4a 3.3±1.2b 
 
Means (± SE) having different superscript small letters within the 
same row are significantly different at (P< 0.05) based on (t-Test) 
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Fig (1): The concentrations of T4 in rabbits treated with prednisolone        
(2.2 mg /Kg Bwt) given I/M compared to the control on day 6 and 
day 12 of the experiment.      
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Fig (2): The concentrations of T3 in rabbits treated with prednisolone        
(2.2 mg /Kg Bwt) given I/M compared to the control on day 6 and 
day 12 of the experiment.       
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3.3 Concentration of serum thyroid stimulating hormone (TSH): 
 The concentrations of TSH on day 6 and day 12 of the 
experiment were presented in Table (1) and Fig. (5).  
On day 6 the mean values of TSH of the treated group was non-
significantly lowered (0.206 ± 0.08) compared to that of the control 
group (0.24 ± 0.1). Also on day 12 the mean values of TSH of the 
treated group (0.14 ± 0.03) were non-significantly decreased  
compared to the control group (0.17 ± 0.05). 
3.4 Concentration of serum luteinizing hormone (LH): 
 The concentrations of LH on day 6 and day 12 of the 
experiment were presented in Table (1) and Fig. (6).  
On day 6 the mean values of LH of the treated group (5.7 ± 2.2) 
were significantly (P< 0.05) reduced compared to the control group 
(11.0 ± 0.22). On day 12 the values of LH of the treated group  (3.3 ± 
1.2) were also significantly (P< 0.05) less than that of the control 
group (13. 9 ± 3.4).  
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 Fig (3):   The concentrations of TSH in rabbits treated with prednisolone 
(2.2 mg /Kg Bwt) given I/M compared to the control on day 6 
and day 12 of the experiment. 
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Fig (4):    The concentrations of LH in rabbits treated with  prednisolone   
(2.2 mg /Kg Bwt) given I/M compared to the control on day 6 
and day 12 of the experiment. 
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CHAPTER FOUR 
DISCUSSION 
 
        Glucocorticoids are extensively used in bone marrow transplant-
ation, solid organ transplantation and treatment of haematological 
malignancies, rheumatoid arthritis and chronic pulmonary conditions 
e.g. asthma (Lionakis and Kontoyiannis, 2003). 
 In veterinary practice huge amounts of dexamethasone and long 
acting dexamethasone are used in our country. Moreover prednisolone 
is incorporated in most of the intra-mammary syringes to treat mastitic 
animals.  
Nowadays, there is a high occurrence of cataract and glaucoma 
among female university students. A Sudanese ophthalmologist 
mentioned in the local press and he claimed that this is due to the 
misuse of hydrocortisone eye drops (Personal communication). The 
widespread use and misuse of glucocorticoids dictates this study and 
still more research work on the effect of glucocorticoids on other 
systems of the body is needed.  
4.1 Serum thyroid hormones: 
In the present study, multiple administration of the synthetic 
glucocorticoid, prednisolone was clearly associated with substantial 
reduction in the serum levels of T4 and T3. Similar reduction in the 
level of both hormones have been observed by Visser and Lamberts 
(1981) in patients with Cushing's syndrome, in healthy dogs after the 
third I/M injection of prednisone 2.2 mg/kg Bwt (Woltz et al., 1983) 
and after 8 days in dogs given oral dose of prednisone 0.55 mg/kg 
Bwt/day (Kurtdede et al., 2004). 
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 Previous studies conducted in healthy human subjects given a 
single dose of betamethasone or dexamethasone failed to detect a 
decline in T4 concentration, but did note a depression in the level of T3 
(Azukizawa et al., 1979; Kemppainen et al., 1983; Woltz et al., 1983). 
In-contrast, in this study the levels of both T4 and T3 were non-
significantly reduced up to the third injection (day 6) indirectly 
demonstrating that a single injection of prednisolone 2.2 mg/kg Bwt 
doesn't cause a significant reduction in the levels of T4 and T3 in 
domestic rabbits, whereas a single injection of prednisone of the same 
dose was able to cause a significant reduction of T3 in the dog (Woltz 
et al., 1983).   
 It is suggested that glucocorticoid induced suppression of T4 
and T3 levels is a dose related phenomenon which may also be 
affected by the route of administration, chemical form of the agent, 
sex of the subject, doses, and treatment duration (Kemppainen et al., 
1983; Kurtdede et al., 2004). 
 One possible explanation for the significant reduction in  
peripheral T4 and T3 levels in rabbits given prednisolone in this study 
is that, glucocorticoid acts directly on the thyroid gland, since 
lysosomal hydrolysis of colloid is a prerequisite for thyroid hormone 
secretion, the well-known stabilizing effect of glucocoricoids on 
lysosomal membranes could account for the cytoplasmic colloid 
accumulation, as revealed by electron microscopic examination of 
thyroid tissue of dogs treated with prednisone, subsequently reducing 
T4 and T3 secretion by inhibiting lysosomal hydrolysis of the colloid in 
the thyroid follicular cells (Kemppainen et al., 1983; Woltz et al., 
1983; Kurtdede et al., 2004).  
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4.2 Serum TSH: 
 In this study the mean values of TSH were not significantly 
reduced on day 6 and day 12 of the experiment. This finding does not 
agree with the study done by Azukizawa et al. (1979), who observed a 
profound reduction in TSH in men given a single dose of 
betamethasone, 8 mg for each man intravenously. The variation is 
possibly due to the potency of the drug, the high dose and the route of 
administration. 
From the physiological point of view, there always exists a 
marked inverse relationship between plasma thyroid hormones and 
plasma TSH. Therefore, fall in thyroid hormones via negative 
feedback mechanism stimulate TSH secretion to cause rise in thyroid 
hormones (Jain, 2005). In-contrast, in the present study, on day12 
there was a non-significant reduction of TSH while thyroid hormones 
were significantly reduced. 
The explanation for these findings is that, low or normal TSH 
and low thyroid hormones test results represent a typical pattern in 
unwell patients with non-thyroidal illness (Lindsay and Toft, 1997; 
Dayan, 2001). Non-endocrinologists are frequently surprised to find 
TSH in the normal range in this situation, since the pituitary fails to 
respond adequately to low thyroid hormones concentration (Dayan, 
2001). In clinical practice this is a greatest challenge in diagnosis of 
the condition. Glucocorticoids, dopamine and dobutamine can 
suppress serum TSH even in patients with overt primary hypo-
thyroidism. Thus, thyroid function testing is best reserved for severely 
ill patients in whom there is a substantial  clinical suspicion of 
hypothyroidism; otherwise abnormal results are much more likely to 
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represent false-positive than true-positive findings (Roberts and 
Ladenson, 2004). 
4.3 Serum luteinizing hormone: 
 In the present study the serum levels of LH were significantly 
decreased on day 6 and day 12 of the experiment. These findings are 
in agreement with a prior study in which administration of para-
methasone acetate 5 mg daily to young women with normal menstrual 
cycles resulted in significantly depressed basal LH levels on the 
second day of administration, this suppression persisted throughout 
most of the menstrual cycle (Cortis-Gallegos et al., 1975). Moreover, 
another study was conducted to determine the effect of short term 
administration of high doses of glucocorticoids on LH and FSH 
secretion and the site of this effect in women with ovulatory cycles. 
There was a significant reduction of the basal levels of LH and FSH 
and the gonadotropins response to GnRH was blunted (Sowers et al., 
1979). 
   It has been observed that patients with Cushing's disease have 
suppressed basal levels of LH and FSH and diminished gonadotropin 
responses to GnRH (Luton et al., 1977). 
 Also this result of LH reduction due to prednisolone treatment 
is in agreement with the result of (Chemtarapreteep and Thibier, 1983) 
who gave a single dose of 20 mg dexamethasone for each treated bull. 
 In an attempt to elucidate the mechanism of suppressive action 
of glucocorticoids on the hypothalamo-pituitary-ovarian axis, the 
effect of short-term high dose of dexamethasone on the LH response 
to GnRH was studied in healthy women with normal menstrual cycles, 
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they received 100 µg of GnRH intravenously on day 6 of two 
consecutive menstrual cycles, once with and once without pre-
treatment with dexamethasone 2 mg/woman orally every 6 hrs, on 
days 2 through 5 of the menstrual cycle. The administration of 
dexamethose suppressed baseline serum level of LH and blunted LH 
response to GnRH. This result indicated that pharmacological doses of 
glucocorticoids suppress the secretion of LH by direct effect on the 
pituitary and possible by an effect at the hypothalamic level with 
inhibition of the release of GnRH (Sowers et al., 1979). Similar 
studies were done by Chantaraprateep and Thibier (1978) in bulls and 
by Kemppainen et al. (1983) in dogs, who produced the same 
explanation. 
Therefore, in the present study, it is suggested that the inhibition 
of LH secretion in domestic rabbits treated with prednisolone was at 
the hypothalamic and the pituitary level.  
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CONCLUSION AND RECOMMENDATION 
 
 It was obvious that glucocorticoids affect thyroid and gonado-
trophic hormones secretion, causing a significant reduction in thyroid 
hormones and luteinizing hormone leading to a great challenge in 
diagnosis of thyroid diseases and interpretation of fertility tests. 
 Thus it is recommended that: 
1. Veterinarians should not use glucocorticoids during estrous 
cycle, in synchronized animals and in males at the time of 
breeding. 
2. People should be informed of the potential side effects of 
glucocorticoids, and the information of patients receiving such 
drugs should be documented in the clinical record. 
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